Search
Entreprise
Back
Qui sommes-nous ?
Back
Qualité et durabilité
Back
Produits
Back
Diagnostics
Back
Oncologie
Back
Service
Back
Qualité
Back
Ressources
Back
Centre d’expertise
Back
Carrière
Back
Pourquoi travailler chez Sysmex ?
Back
Votre carrière chez Sysmex
Back
Menu
Headquarters
Sysmex Group Companies
Select your local website
Life Science
13th International Symposium on Minimal Residual Cancer (ISMRC)
13th International Symposium on Minimal Residual Cancer
The ISMRC meetings were initiated in 1996 and have established themselves as premier events focusing on biology, technologies and in particular clinical applications of “Liquid Biopsy” in cancer patients.
This international meeting is a great opportunity to gather for three days and share information on the most recent developments with leading researchers in the oncology, immunology and liquid biopsy fields.
Join us at booth #N10 on 2–4 May in Hamburg for the latest Plasma SeqSensei™ Cancer IVD Kits and discover how Sysmex Life Science brings liquid biopsy closer to the patient.
You’ll find further information in the invitation attached and more on our Plasma-SeqSensei™ Cancer IVD Kits here:
Ateliers
2023/05/02
| 16:15
— 18:15
Poster presentations
| Routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using the Plasma-SeqSensei™ NSCLC RUO Kit at diagnostic in Lyon’s hospital. |
|
| Identifying the levers of cost-effectiveness of next generation-sequencing-based liquid biopsy for colorectal cancer in France, Spain and Germany |
|
| Improved detection of disease progression in metastatic breast cancer by absolute molecular counting: the 100 copies/mL question |
|
| Development of a target-capture NGS assay for use in molecular-based research of myeloid measurable residual disease. |
|
2023/05/03
| 13:15
— 13:45
Meet the expert session
| Monitoring of treatment response and recurrence with Plasma-SeqSensei™ in melanoma patients |
|
2023/05/04
| 09:00
— 09:20
ISMRC symposia
| Screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using three targeted assays |
|